Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Benitec Biopharma Inc

BNTC ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$12.56

▲ +0.00%

Market Cap $431.49M · Vol 55.48K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$431.49M

Small Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+3.40%

YoY

RSI (14)

60.79

Momentum

Beta

0.24

vs Market

52W High

$16.65

24.56% below

52W Low

$9.95

26.23% above

Volume

55.48K

Avg 35.54K

P/B

3.16

Price-to-book

ROE

N/A

Return on equity

Free Float

97.45%

Public shares

Shariah Compliance8 STANDARDS

✗ Benitec Biopharma Inc (BNTC) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BNTC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.85%

-3.24%

+5.99%

+21.00%

YTD

-6.76%

-0.79%

+366.91%

-81.48%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-37,917,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-49.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.16
P/FCF	N/A
EPS Growth	+3.40%
Outstanding Shares	34.35M

Technical Indicators

50-Day SMA	$12.31
200-Day SMA	$12.22
RSI (14)	60.79
Beta	0.24
52-Week High	$16.65
52-Week Low	$9.95

Volume Today	55.48K
Avg Daily Volume (30D)	35.54K
Relative Volume	1.56x
Volatility (10D)	57.52
Volatility (30D)	43.92
Free Float	97.45%

Analyst Consensus

BUY

Current Price $12.56

Mean Target $24.17

52W Low$9.95 52W High$16.65

Current

Target

$9.95 $16.65

Current Analyst target

+92.41% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00R712L65

ISINUS08205P2092

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateSep 25, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.